BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 23, 2004
View Archived Issues
Neurochem Signs Potential $54M Deal With Centocor For Fibrillex
Just a few weeks after completing the treatment portion of a Phase II/III trial of Fibrillex, Neurochem Inc. partnered its AA amyloidosis drug with Centocor Inc. in a deal worth up to $54 million. (BioWorld Today)
Read More
Isis Sells Macugen Royalties: $24M To Push Pipeline Drugs
Read More
Symbollon Beginning Phase III With Product For Breast Pain
Read More
Creative Thinking Required For Debate Over Follow-On Biologics
Read More
Correction
Read More
Other News To Note
Read More
Appointments And Advancements
Read More